Pharma Giants Make Big Bets on AI to Boost Drug Discovery and Efficiency
-
Eli Lilly is investing heavily in AI drug discovery through partnerships with companies like Atomwise, Verge Genomics, and XtalPi. Over $1 billion committed so far.
-
AstraZeneca launched an AI business called Evinova to improve clinical trial design and operations. Also partnering with Absci on AI-discovered cancer drug.
-
Novartis taking more conservative approach, using AI to streamline operations and tackle difficult medical chemistry problems. Invested in Yseop for regulatory writing.
-
Major players taking varied approaches to tap into AI, from direct drug discovery to back-office optimization. Too early to pick winners.
-
Article highlights Lilly, AstraZeneca and Novartis as making big AI plays, sees them positioned to be leaders in leveraging AI.